Compounds > 10,11-methylenedioxy-20-camptothecin
Page last updated: 2024-12-06

10,11-methylenedioxy-20-camptothecin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

10,11-Methylenedioxy-20-camptothecin (MDX-CPT) is a synthetic derivative of camptothecin, a natural product with potent antitumor activity. It has been studied extensively for its potential to treat various types of cancer. MDX-CPT is a topoisomerase I inhibitor, which means it prevents the enzyme from properly unwinding and re-winding DNA. This interruption in DNA replication leads to cell death. MDX-CPT is also known to have anti-angiogenic activity, meaning it can inhibit the growth of new blood vessels. This property is particularly relevant to cancer treatment, as tumors require a constant supply of blood to grow and spread. MDX-CPT has been investigated in clinical trials for treating a variety of cancers, including colorectal cancer, lung cancer, and ovarian cancer. It has shown promising results in some studies, but further research is needed to determine its optimal use and potential side effects. The synthesis of MDX-CPT involves modifying the camptothecin molecule with a methylenedioxy group at positions 10 and 11. This modification enhances the drug's potency and stability. The study of MDX-CPT is driven by its potential to improve cancer treatment outcomes. Research focuses on understanding its mechanisms of action, optimizing its delivery, and exploring potential combinations with other anticancer therapies. MDX-CPT remains a promising target for the development of new anticancer drugs.'
```

10,11-methylenedioxy-20-camptothecin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72403
CHEMBL ID307794
SCHEMBL ID18296600
MeSH IDM0183098

Synonyms (36)

Synonym
135415-73-5
7-ethyl-7-hydroxy-(7s)-7,8,11,13-tetrahydro-10h-[1,3]dioxolo[4,5-g]pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-8,11-dione
7-ethyl-7-hydroxy-(7s)-7,8,11,13-tetrahydro-10h-[1,3]dioxolo[5,4-g]pyrano[3'''',4'''':6,7]indolizino[1,2-b]quinoline-8,11-dione
bdbm50036133
10h-1,5-g]pyrano[3',4':6,7]indolizino[1,2-b] quinoline-8,11(7h,12h)-dione, 7-ethyl-7-hydroxy-, (s)-
nsc-634724
NCI60_011589
104155-89-7
mdo-cpt
10,11-methylenedioxy-20s-camptothecin
nsc634724
10,11-ch2o2-camptothecin
10,11-methylenedioxy-camptothecin
10,11-methylenedioxycamptothecin
CHEMBL307794 ,
10,11-methylenedioxy-20-camptothecin
10,11-methylenedioxy-20-(rs)-camptothecin
10h-1,3-dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7h,13h)-dione, 7-ethyl-7-hydroxy-, (+-)-
10h-1,3-dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7h,13h)-dione, 7-ethyl-7-hydroxy-, (7s)-
10,11-(methylenedioxy)-20(s)-camptothecin
10h-1,3-dioxolo(4,5-g)pyrano(3,4:6,7)indolizino(1,2-b)quinoline-8,11(7h,13h)-dione, 7-ethyl-7-hydroxy-, (7s)-
compound 5z [pmid: 8410981]
gtpl8893
SCHEMBL18296600
HY-12486
RPFYDENHBPRCTN-NRFANRHFSA-N
Q27076760
(5s)-5-ethyl-5-hydroxy-7,18,20-trioxa-11,24-diazahexacyclo[11.11.0.02,11.04,9.015,23.017,21]tetracosa-1(13),2,4(9),14,16,21,23-heptaene-6,10-dione
(s)-7-ethyl-7-hydroxy-7h-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11(10h,13h)-dione
EX-A4324
MS-26554
7-ethyl-7-hydroxy-2h,10h-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11(7h,13h)-dione
DTXSID20908832
A935094
(s)-7-ethyl-7-hydroxy-10,13-dihydro-11h-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11(7h)-dione
CS-0011782

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In the present investigation, the pharmacokinetic behavior of CA, its sodium salt CA, AC, and MC in mice was characterized using specific liquid chromatographic assays which permitted determination of the intact lactone and opened ring carboxylate forms of these compounds."( Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice.
Malspeis, L; Supko, JG, 1993)		0.29

Bioavailability

ExcerptReferenceRelevance
" Because the CPTs have poor bioavailability and are unable to cross the blood-brain barrier, they may best be delivered to the central nervous system by polymers."( Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Alderson, LM; Amundson, E; Brem, H; Colvin, M; Sampath, P; Tyler, BM; Wall, ME; Wani, MC; Weingart, JD, 2003)		0.32

Dosage Studied

ExcerptRelevanceReference
" Intact lactone plasma levels achieved after dosing with the lactone form of CA and its 9-amino and 10,11-methylenedioxy derivatives exceeded the far less active carboxylate at all times."( Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice.
Malspeis, L; Supko, JG, 1993)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)0.05250.02101.862610.0000AID210946; AID56570
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 1Homo sapiens (human)EC50 (µMol)0.05000.05000.33592.0150AID240049
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay IDTitleYearJournalArticle
AID94454Number of metastases in K1735-M2 murine melanoma cells after subcutaneous administration on days1,4,6,8 at dose of 3 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
AID1854801Induction of apoptosis in human NCI-H69AR cells assessed as late apoptotic cells at 1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 2.99 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854797Induction of apoptosis in human NCI-H446 cells assessed as early apoptotic cells at 10 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 2.43 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854812Induction of apoptosis in human NCI-H446 cells assessed as increase in cleaved-PARP protein expression at 0.1 to 100 nM measured after 24 hrs by Western blot analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854793Induction of apoptosis in human NCI-H446 cells assessed as dead cells at 0.1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 0.33 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854803Induction of apoptosis in human NCI-H69AR cells assessed as early apoptotic cells at 10 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 0.35 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID247882Concentration required to inhibit growth of human cervical HeLa carcinoma cell line2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
AID240049Effective concentration against DNA topoisomerase I2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
AID83940Tumor volume in HT-29 cells after subcutaneous administration on days 16,20,23,27,30,34,37,41,44,48 at dose of 3 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
AID1854777Antiproliferative activity against human NCI-H69AR cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID223513Relative survival in RAW117-H10 cells implanted mice in comparison to control at dose of 3 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
AID1854856Resistance index, ratio of IC50 for antiproliferative activity against Irinotecan-resistant human NCI-H446 cells to IC50 for antiproliferative activity against human NCI-H446 cells2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854795Induction of apoptosis in human NCI-H446 cells assessed as late apoptotic cells at 1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 1.55 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854796Induction of apoptosis in human NCI-H446 cells assessed as dead cells at 1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 0.33 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854772Antiproliferative activity against human 2008 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID223505Relative survival in L1210 lymphoid leukemic mice after subcutaneous administration on days 1,4,6,8 at dose of 3 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
AID1854780Antiproliferative activity against human NCI-H69 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID242837Stability constant for DNA topoisomerase I complex in competitive DNA assay2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
AID237674Half life of compound for DNA topoisomerase I complex was determined2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
AID247883Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
AID1854774Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID210946Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
AID1854778Antiproliferative activity against human SH-SY5Y cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854804Induction of apoptosis in human NCI-H69AR cells assessed as late apoptotic cells at 10 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 2.99 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854775Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854794Induction of apoptosis in human NCI-H446 cells assessed as early apoptotic cells at 1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 2.43 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854808Induction of apoptosis in human NCI-H69AR cells assessed as dead cells at 100 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 1.92 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854805Induction of apoptosis in human NCI-H69AR cells assessed as dead cells at 10 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 1.92 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854858Resistance index, ratio of IC50 for antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells to IC50 for antiproliferative activity against human NCI-H446 cells2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854807Induction of apoptosis in human NCI-H69AR cells assessed as late apoptotic cells at 100 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 2.99 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854813Induction of apoptosis in human NCI-H446 cells assessed as increase in cleaved-caspase 9 protein expression at 0.1 to 100 nM measured after 24 hrs by Western blot analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854806Induction of apoptosis in human NCI-H69AR cells assessed as early apoptotic cells at 100 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 0.35 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854773Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854791Induction of apoptosis in human NCI-H446 cells assessed as early apoptotic cells at 0.1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 2.43 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854800Induction of apoptosis in human NCI-H69AR cells assessed as early apoptotic cells at 1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 0.35 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854857Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854798Induction of apoptosis in human NCI-H446 cells assessed as late apoptotic cells at 10 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 1.55 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854776Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID211091The compound was tested for top1-induced DNA cleavage activity; +++ indicates much more potent than CPT1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
AID1854779Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854802Induction of apoptosis in human NCI-H69AR cells assessed as dead cells at 1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 1.92 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID56570Inhibition of topoisomerase I activity was determined in vitro by using the cleavable complex assay(calf thymus)1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I.
AID1854814Induction of apoptosis in human NCI-H446 cells assessed as increase in cleaved-caspase 3 protein expression at 0.1 to 100 nM measured after 24 hrs by Western blot analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854855Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854799Induction of apoptosis in human NCI-H446 cells assessed as dead cells at 10 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 0.33 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854781Antiproliferative activity against human U87 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854792Induction of apoptosis in human NCI-H446 cells assessed as late apoptotic cells at 0.1 nM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry analysis (Rvb = 1.55 %)2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
AID1854849Antitumor activity against human NCI-H446 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 3 mg/kg, IG administered once a week for 28 days by electronic caliper method relative to control2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (53.85)18.2507
2000's4 (30.77)29.6817
2010's1 (7.69)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.94 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycine
[no description available]		210alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
LSM-1442
[no description available]		1.9810pyranoindolizinoquinoline
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		2.0110N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		3.87120delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
etoposide
[no description available]		2.4110beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.7130pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
irinotecan
[no description available]		2.7330carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
lurtotecan
lurtotecan: NX-211 is the low-clearance liposomal formulation; structure in first source		1.9910
9-aminocamptothecin
[no description available]		2.3820pyranoindolizinoquinoline
10-hydroxycamptothecin
[no description available]		1.9810pyranoindolizinoquinoline
sn 38
SN-38 : A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself.		2.4120delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol		antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
7-ethyl-7-hydroxy-10h-1,3-dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7h,12h)-dione
7-ethyl-7-hydroxy-10H-1,3-Dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7H,12H)-dione: an antineoplastic agent that inhibits survivin, Mcl-1, and cIAP2; structure in first source		1.9810
aphidicolin
Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication.		1.9710tetracyclic diterpenoidantimicrobial agent;
antimitotic;
antineoplastic agent;
antiviral drug;
apoptosis inducer;
Aspergillus metabolite;
DNA synthesis inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
fungal metabolite
nsc 100880
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9810
Carcinoma, Small Cell Lung
[description not available]		02.4110
Cancer of Lung
[description not available]		02.4110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.4110
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		02.4110
Keloid
A sharply elevated, irregularly shaped, progressively enlarging scar resulting from formation of excessive amounts of collagen in the dermis during connective tissue repair. It is differentiated from a hypertrophic scar (CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding tissues.		02.110
Breast Cancer
[description not available]		0210
Breast Neoplasms
Tumors or cancer of the human BREAST.		0210
Glial Cell Tumors
[description not available]		02.0110
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.0110
Cancer of Colon
[description not available]		02.3820
Colonic Neoplasms
Tumors or cancer of the COLON.		02.3820